1. Home
  2. LH vs INSM Comparison

LH vs INSM Comparison

Compare LH & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laboratory Corporation of America Holdings

LH

Laboratory Corporation of America Holdings

HOLD

Current Price

$255.36

Market Cap

21.7B

Sector

Health Care

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$95.25

Market Cap

23.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LH
INSM
Founded
1971
1988
Country
United States
United States
Employees
70000
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7B
23.0B
IPO Year
2005
2000

Fundamental Metrics

Financial Performance
Metric
LH
INSM
Price
$255.36
$95.25
Analyst Decision
Buy
Strong Buy
Analyst Count
9
24
Target Price
$311.33
$201.17
AVG Volume (30 Days)
512.3K
3.7M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.12%
N/A
EPS Growth
18.33
N/A
EPS
3.35
N/A
Revenue
$13,951,700,000.00
N/A
Revenue This Year
$8.26
$182.31
Revenue Next Year
$4.81
$65.19
P/E Ratio
$76.33
N/A
Revenue Growth
7.25
N/A
52 Week Low
$241.81
$90.39
52 Week High
$293.72
$212.75

Technical Indicators

Market Signals
Indicator
LH
INSM
Relative Strength Index (RSI) 42.18 38.07
Support Level $248.61 $90.39
Resistance Level $274.48 $166.81
Average True Range (ATR) 5.90 5.25
MACD -0.43 0.88
Stochastic Oscillator 12.60 32.99

Price Performance

Historical Comparison
LH
INSM

About LH Laboratory Corporation of America Holdings

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: